WDR77: A Potential Drug Target and Biomarker for Various Diseases

Target Name: WDR77

NCBI ID: G79084

WDR77: A Potential Drug Target and Biomarker for Various Diseases

WDR77 (Wnt-Difensin) is a protein that is expressed in various tissues throughout the body, including the nervous system, and has been shown to play a role in the development and progression of various diseases, including cancer. In addition, WDR77 has also been identified as a potential drug target and biomarker.

WDR77 is a member of the Wnt family, which is known for their role in the development and maintenance of tissues during embryonic development. The Wnt family includes several proteins, including Wnt1, Wnt3, Wnt4, and Wnt5, which have been implicated in the development of various diseases, including cancer.

WDR77 is a 70-kDa protein that is expressed in various tissues throughout the body, including the brain, spinal cord, and lymphoid organs. It is composed of 116 amino acid residues and has a calculated pI of 1.9. WDR77 is primarily localized to the peri-glial tissue, which is the surrounding tissue that surrounds the CNS and includes the meninges, which are the protective membranes that cover the brain and spinal cord.

WDR77 has been shown to play a role in the development and progression of various diseases, including cancer. For example, studies have shown that high levels of WDR77 are associated with poor prognosis in patients with diffuse large B-cell lymphoma, a type of cancer that affects the lymphatic system. Additionally, WDR77 has also been shown to be overexpressed in various types of cancer, including breast, ovarian, and colorectal cancer.

In addition to its role in cancer, WDR77 has also been identified as a potential drug target. Its high expression in various tissues make it a promising target for small molecules, which can be used to inhibit its activity and reduce the growth of cancer cells. Additionally, its role in the development and progression of various diseases also makes it an attractive target for drugs that aim to prevent or reverse the effects of these diseases.

WDR77 has been shown to interact with several drug targets, including the TGF-β pathway. This pathway is involved in the regulation of cell growth, differentiation, and survival, and has been implicated in the development and progression of various diseases, including cancer. Studies have shown that inhibiting TGF-β signaling can inhibit the activity of WDR77 and reduce the growth of cancer cells.

In addition to its potential as a drug target, WDR77 has also been identified as a potential biomarker. Its expression has been shown to be elevated in various types of cancer, including breast, ovarian, and colorectal cancer. This makes it a potential marker for these diseases and could be used in the development of diagnostic tests and treatments.

Overall, WDR77 is a protein that has the potential to be a drug target or biomarker for various diseases. Its role in the development and progression of cancer, as well as its potential interactions with drug targets, make it an attractive target for small molecules and researchers are actively working on identifying and developing compounds that can inhibit its activity. As more research is conducted, WDR77 is likely to become a valuable tool for the treatment of various diseases.

Protein Name: WD Repeat Domain 77

Functions: Non-catalytic component of the methylosome complex, composed of PRMT5, WDR77 and CLNS1A, which modifies specific arginines to dimethylarginines in several spliceosomal Sm proteins and histones (PubMed:11756452). This modification targets Sm proteins to the survival of motor neurons (SMN) complex for assembly into small nuclear ribonucleoprotein core particles. Might play a role in transcription regulation. The methylosome complex also methylates the Piwi proteins (PIWIL1, PIWIL2 and PIWIL4), methylation of Piwi proteins being required for the interaction with Tudor domain-containing proteins and subsequent localization to the meiotic nuage (PubMed:23071334)

More Common Targets